These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 8627865)

  • 61. Maximal androgen blockade (MAB) for the treatment of prostate cancer.
    Kirby RS
    Br J Clin Pract; 1996; 50(5):287. PubMed ID: 8794610
    [No Abstract]   [Full Text] [Related]  

  • 62. Molecular implications of the antiandrogen withdrawal syndrome.
    Moul JW; Srivastava S; McLeod DG
    Semin Urol; 1995 May; 13(2):157-63. PubMed ID: 7543690
    [No Abstract]   [Full Text] [Related]  

  • 63. Alternative antiandrogen therapy in patients with castration-resistant prostate cancer: a single-center experience.
    Okegawa T; Nutahara K; Higashihara E
    Int J Urol; 2010 Nov; 17(11):950-5. PubMed ID: 20807265
    [TBL] [Abstract][Full Text] [Related]  

  • 64. What to do when prostate cancer returns.
    Johns Hopkins Med Lett Health After 50; 2003 Jan; 14(11):6. PubMed ID: 12532917
    [No Abstract]   [Full Text] [Related]  

  • 65. Residual prostate cancer in patients treated with endocrine therapy with or without radical radiotherapy: a side study of the SPCG-7 randomized trial.
    Solberg A; Haugen OA; Viset T; Bergh A; Tasdemir I; Ahlgren G; Widmark A; Angelsen A
    Int J Radiat Oncol Biol Phys; 2011 May; 80(1):55-61. PubMed ID: 20598453
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Re: Quality of life in advanced prostate cancer: results of a randomized therapeutic trial.
    Caubet JF
    J Natl Cancer Inst; 1999 Feb; 91(4):381-2. PubMed ID: 10050874
    [No Abstract]   [Full Text] [Related]  

  • 67. [Antiandrogen in prostate cancer].
    Maeda O; Usami M
    Nihon Rinsho; 2002 Dec; 60 Suppl 11():188-92. PubMed ID: 12599569
    [No Abstract]   [Full Text] [Related]  

  • 68. Cost-effectiveness of prostate cancer screening and treatment.
    Bilgrami S; Greenberg B
    Ann Intern Med; 1993 Nov; 119(10):1054-5. PubMed ID: 8214992
    [No Abstract]   [Full Text] [Related]  

  • 69. Flutamide-induced acute renal failure in a patient with metastatic prostate cancer.
    Altiparmak MR; Bilici A; Kisacik B; Ozguroglu M
    Med Oncol; 2002; 19(2):117-9. PubMed ID: 12180480
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Flutamide plus castration in patients with previously untreated prostate cancer.
    Labrie F
    Urology; 1997 Sep; 50(3):479. PubMed ID: 9301724
    [No Abstract]   [Full Text] [Related]  

  • 71. Total androgen blockade in the treatment of hormone-resistant metastasized prostate carcinoma. A literature review.
    Oosterlinck W; Mast P
    Acta Urol Belg; 1994 Apr; 62(1):67-71. PubMed ID: 8197932
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Flutamide photosensitivity.
    Leroy D; Dompmartin A; Szczurko C
    Photodermatol Photoimmunol Photomed; 1996 Oct; 12(5):216-8. PubMed ID: 9112281
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Aspirin and hormone therapy for prostate cancer.
    D'Amico AV; Kantoff PW; Chen MH
    N Engl J Med; 2007 Dec; 357(26):2737-8. PubMed ID: 18160699
    [No Abstract]   [Full Text] [Related]  

  • 74. Flutamide photosensitivity--residual vitiliginous lesions.
    Vilaplana J; Romaguera C; Azón A; Lecha M
    Contact Dermatitis; 1998 Feb; 38(2):68-70. PubMed ID: 9506217
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Flutamide in hormone-resistant prostatic cancer.
    Fosså SD; Hosbach G; Paus E
    J Urol; 1990 Dec; 144(6):1411-4. PubMed ID: 1700154
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Hormone and antihormone withdrawal: implications for the management of androgen-independent prostate cancer.
    Scher HI; Zhang ZF; Nanus D; Kelly WK
    Urology; 1996 Jan; 47(1A Suppl):61-9. PubMed ID: 8560680
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Flutamide-induced photoleukomelanoderma.
    Higashiyama A; Yokoyama T; Omoto Y; Habe K; Yamanaka K; Mizutani H
    J Dermatol; 2016 Sep; 43(9):1105-6. PubMed ID: 26970547
    [No Abstract]   [Full Text] [Related]  

  • 78. A rationale for the use of non-steroidal anti-androgens in the management of prostate cancer.
    Benson RC
    Prostate Suppl; 1992; 4():85-90. PubMed ID: 1574463
    [TBL] [Abstract][Full Text] [Related]  

  • 79. ADT intensification to treat biochemically recurrent prostate cancer.
    Masone MC
    Nat Rev Urol; 2024 Mar; 21(3):126. PubMed ID: 38355924
    [No Abstract]   [Full Text] [Related]  

  • 80. Methemoglobinemia in a patient receiving flutamide.
    Jackson SH; Barker SJ
    Anesthesiology; 1995 Apr; 82(4):1065-7. PubMed ID: 7717540
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.